Ablynx NV - Product Pipeline Review - 2016

Published: May, 2016 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ablynx NV - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Ablynx NV - Product Pipeline Review - 2016', provides an overview of the Ablynx NV's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Ablynx NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Ablynx NV
- The report provides overview of Ablynx NV including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Ablynx NV's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Ablynx NV's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Ablynx NV's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Ablynx NV
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ablynx NV's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Ablynx NV Snapshot 6
Ablynx NV Overview 6
Key Information 6
Key Facts 6
Ablynx NV - Research and Development Overview 7
Key Therapeutic Areas 7
Ablynx NV - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Ablynx NV - Pipeline Products Glance 16
Ablynx NV - Late Stage Pipeline Products 16
Phase III Products/Combination Treatment Modalities 16
Ablynx NV - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Ablynx NV - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Ablynx NV - Drug Profiles 21
caplacizumab 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ALX-0061 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ozoralizumab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ALX-0171 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ALX-0141 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibodies for Immunology and Oncology 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibodies for Inflammation and Osteoarthritis 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibodies for Multiple Sclerosis 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody for Undisclosed Indication 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody to Target c-Met for Multiple Myeloma 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TLC-520 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibodies to Agonize GITR for Immunology and Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody 1 for Oncology 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclonal Antibody 2 for Oncology 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Ablynx NV - Pipeline Analysis 39
Ablynx NV - Pipeline Products by Target 39
Ablynx NV - Pipeline Products by Route of Administration 40
Ablynx NV - Pipeline Products by Molecule Type 41
Ablynx NV - Pipeline Products by Mechanism of Action 42
Ablynx NV - Recent Pipeline Updates 43
Ablynx NV - Dormant Projects 51
Ablynx NV - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
BI-1034020 52
Ablynx NV - Company Statement 53
Ablynx NV - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Ablynx NV, Key Information 6
Ablynx NV, Key Facts 6
Ablynx NV - Pipeline by Indication, 2016 8
Ablynx NV - Pipeline by Stage of Development, 2016 10
Ablynx NV - Monotherapy Products in Pipeline, 2016 11
Ablynx NV - Partnered Products in Pipeline, 2016 12
Ablynx NV - Partnered Products/ Combination Treatment Modalities, 2016 13
Ablynx NV - Out-Licensed Products in Pipeline, 2016 14
Ablynx NV - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
Ablynx NV - Phase III, 2016 16
Ablynx NV - Phase II, 2016 17
Ablynx NV - Phase I, 2016 18
Ablynx NV - Preclinical, 2016 19
Ablynx NV - Discovery, 2016 20
Ablynx NV - Pipeline by Target, 2016 39
Ablynx NV - Pipeline by Route of Administration, 2016 40
Ablynx NV - Pipeline by Molecule Type, 2016 41
Ablynx NV - Pipeline Products by Mechanism of Action, 2016 42
Ablynx NV - Recent Pipeline Updates, 2016 43
Ablynx NV - Dormant Developmental Projects,2016 51
Ablynx NV - Discontinued Pipeline Products, 2016 52
Ablynx NV, Subsidiaries 55